Annual report and Remuneration report 2022 for Initiator Pharma A/S

Regulatory

Initiator Pharma’s Annual Report 2022 and Remuneration Report 2022 has now been published and is available on the company´s home page.

http://initiatorpharma.com/investors/financial-reports/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: [email protected]

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – IP2015 and IP2018 – and two preclinical assets. The company is currently conducting a Phase 2b trial with IP2015 in erectile dysfunction of organic origin, and successfully completed a Phase 1 proof of principle trial in neuropathic pain in 2022. With IP2018 the company is conducting a Phase 2a trial for the treatment of erectile dysfunction of psychogenic origin.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Initiator Pharma AnnualReport2022, FINAL

Documents